

**INTEGRATED MEDICINES OPTIMISATION COMMITTEE**

**COMMISSIONING STATEMENT ON THE USE OF LATANOPROST-NETARSUDIL IN PREVIOUSLY TREATED OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION**

<b>SUMMARY</b> <p>NHS Dorset commissions the use of latanoprost-netarsudil (Roclanda®) in previously treated open angle glaucoma or ocular hypertension, in line with NICE <a href="#">TA1009</a>.</p>	
<b>BACKGROUND</b>	<p><b>Mechanism of action</b></p> <p>Although both latanoprost and netarsudil lower IOP by increasing aqueous humor outflow, their mechanisms of action are different. Studies suggest that the main mechanism of action for netarsudil, a Rho kinase inhibitor, is increased trabecular outflow. These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure.</p> <p><b>Marketing authorisation</b></p> <p>Latanoprost-netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.</p>
<b>RELEVANT NICE GUIDANCE</b>	<p>Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (NICE <a href="#">TA1009</a>) states:</p> <ul style="list-style-type: none"> <li>• Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if: <ul style="list-style-type: none"> <li>○ they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or</li> <li>○ a fixed-dose combination treatment containing beta-blockers is unsuitable.</li> </ul> </li> </ul>
<b>FORMULARY STATUS</b>	Green
<b>NHS PAYMENT SCHEME STATUS</b>	Not listed within the NHS Payment scheme as an excluded high cost drug.
<b>COMMISSIONING IMPLICATIONS</b>	<p>In line with the NICE TA, this product would be used only after use of</p> <ul style="list-style-type: none"> <li>• Prostaglandin analogue monotherapy, then</li> <li>• Fixed dose combination treatment with prostaglandin analogue and beta blocker has not reduced intraocular pressure enough (or where a fixed dose option containing beta blocker is unsuitable); alongside other options outlined in <a href="#">NICE CKS</a></li> </ul>
<b>RELEVANT CLINICAL WORKING GROUP</b>	Ophthalmology

<b>PATIENT PATHWAY IMPLICATIONS</b>	Usual treatment for reducing IOP in people with primary open-angle glaucoma or ocular hypertension includes a prostaglandin analogue eye drop (for example, bimatoprost or latanoprost). If this does not work well enough, people usually have a fixed-dose combination treatment eye drop. These include combinations of a prostaglandin analogue with a beta-blocker (for example, bimatoprost–timolol), or a prostaglandin analogue with carbonic anhydrase inhibitors or sympathomimetics. Latanoprost–netarsudil is a fixed-dose combination treatment containing a prostaglandin analogue with a Rho kinase inhibitor which would be used where other fixed dose combinations have not worked well enough or a combination with beta-blockers is unsuitable.
<b>SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS</b>	<p>Clinical trial evidence suggests that latanoprost–netarsudil is as effective as bimatoprost–timolol. Indirect comparisons of latanoprost–netarsudil with other fixed-dose combination treatments are highly uncertain, but suggest that they have similar effectiveness.</p> <p>A cost comparison suggests that latanoprost–netarsudil has similar or lower costs than most branded fixed-dose combination treatments. These are usually used after a fixed-dose combination treatment has not reduced IOP enough. Latanoprost–netarsudil also has similar or lower costs compared with some generic fixed-dose combination treatments. So, latanoprost–netarsudil is recommended.</p>
<b>PRESCRIBING INFORMATION</b>	The recommended dosage is one drop in the affected eye(s) once daily in the evening. Patients should not instill more than one drop in the affected eye(s) each day. In vitro interaction studies have shown that precipitation can occur when eye drops containing thimerosal are mixed with latanoprost + netarsudil. Administer other eye drops at least five minutes apart
<b>ASSESSMENT OF COST IMPLICATIONS</b>	<p>A cost comparison suggests that latanoprost–netarsudil has similar or lower costs than most branded fixed-dose combination treatments. Latanoprost–netarsudil also has similar or lower costs compared with some generic fixed-dose combination treatments.</p> <p>The list price of latanoprost-netarsudil (2.5ml bottle) is £14.00. Annual cost of treatment for one eye = £182</p>
<b>REFERENCES</b>	<p>Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (NICE <a href="#">TA1009</a>) (published 2 October 2024)</p> <p><a href="#">Summary of product characteristics of Roclanda®</a> (accessed via the electronic medicines compendium – last updated May 2023)</p> <p><a href="#">Online drug tariff</a> (access 11/10/2024)</p>
<b>DATE</b>	October 2024
<b>REVIEW DATE</b>	September 2026 or before, in light of new information.
<b>CONTACT FOR THIS POLICY</b>	<a href="mailto:medicine.question@nhsdorset.nhs.uk">medicine.question@nhsdorset.nhs.uk</a>